Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

5.790 -0.830 (-12.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 143,104
Open 6.470
Bid (Size) 5.510 (600)
Ask (Size) 6.160 (100)
Prev. Close 6.620
Today's Range 5.620 - 6.470
52wk Range 3.350 - 17.94
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode... 
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-56.1%
-56.1%
1 Month
+8.8%
+8.8%
3 Month
+40.9%
+40.9%
6 Month
-53.6%
-53.6%
1 Year
-31.8%
-31.8%

More News

Read More
News headline image
Important Notice to Long-Term Shareholders Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); GoDaddy Inc. (NYSE: GDDY); and Hub Group, Inc. (NASDAQ: HUBG); Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Deadline Alert: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aardvark Therapeutics, Inc. (AARD)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Deadline Soon: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Oct. 31st DEADLINE ALERT: Investors Who Lost Money With Aardvark Therapeutics, Inc. (NASDAQ: AARD) Shares Should Contact the Shareholders Foundation in Connection With Lawsuit
From The Shareholders Foundation, Inc.
Via Business Wire
News headline image
Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD
Via Newsfile
Topics Initial Public Offering Lawsuit
News headline image
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Aardvark Therapeutics, Inc. (AARD) Encourages Shareholders To Inquire About Securities Fraud Class Action
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Law Offices of Howard G. Smith Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Law Offices of Frank R. Cruz Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire About Securities Fraud Class Action
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD
From The DJS Law Group
Via Business Wire
News headline image
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Aardvark Therapeutics, Inc. (AARD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of Aardvark Therapeutics, Inc. (NASDAQ: AARD) to Contact the Firm to Learn About Their Legal Rights
Via NewMediaWire
Topics Initial Public Offering Lawsuit
News headline image
AARD Stockholder Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Aardvark Therapeutics, Inc.
From Robbins LLP
Via Business Wire

Frequently Asked Questions

Is Aardvark Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aardvark Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aardvark Therapeutics, Inc. - Common Stock trade on?
Aardvark Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aardvark Therapeutics, Inc. - Common Stock?
The ticker symbol for Aardvark Therapeutics, Inc. - Common Stock is AARD on the Nasdaq Stock Market
What is the current price of Aardvark Therapeutics, Inc. - Common Stock?
The current price of Aardvark Therapeutics, Inc. - Common Stock is 5.790
When was Aardvark Therapeutics, Inc. - Common Stock last traded?
The last trade of Aardvark Therapeutics, Inc. - Common Stock was at 08/28/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.